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Abstract: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disorder caused by homozygous mutations of the SMN1 gene. Based on clinical severity, 
three forms of SMA are recognized (type I–III). All patients have at least one (usually 2–4) 
copies of a highly homologous gene (SMN2) which produces insufficient levels of 
functional SMN protein, due to alternative splicing of exon7. Recently, evidence has been 
provided that SMN2 expression can be enhanced by different strategies. The availability of 
potential candidates to treat SMA has raised a number of issues, including the availability 
of data on the natural history of the disease, the reliability and sensitivity of outcome 
measures, the duration of the studies, and the number and clinical homogeneity of 
participating patients. Equally critical is the availability of reliable biomarkers. So far, 
different tools have been proposed as biomarkers in SMA, classifiable into two groups: 
instrumental (the Compound Motor Action Potential, the Motor Unit Number Estimation, 
and the Dual-energy X-ray absorptiometry) and molecular (SMN gene products dosage, 
either transcripts or protein). However, none of the biomarkers available so far can be 
considered the gold standard. Preclinical studies on SMA animal models and double-blind, 
placebo-controlled studies are crucial to evaluate the appropriateness of biomarkers, on the 
basis of correlations with clinical outcome.  
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1. Introduction  
Proximal spinal muscular atrophies (SMA) are a group of clinically variable motor neuron disorders 
characterized by the degeneration of the anterior horn cells of the spinal cord. On the basis of age of 
onset and of the maximum motor achievement, childhood-onset SMA is generally classified into three 
forms (type I to III). Type I is the most severe and common form of SMA and the most frequent cause 
of infantile mortality due to genetic cause. The onset of symptoms is generally between birth and six 
months of age, although in rare cases the first manifestations of the disease may occur during fetal life; 
patients show marked hypotonia, affecting mainly axial and proximal muscles, and do not achieve the 
seated position. Life expectancy is markedly reduced, generally less than two years of age, the main 
cause of death being respiratory insufficiency. Type II is an intermediate form, generally characterized 
by onset before 18 months of age. Affected children do not achieve autonomous ambulation. Type III 
is clinically the most variable form: the onset of symptoms is over 18 months of age, the motor 
milestones achievement is normal; patients may lose the walking ability at various ages. Type II and 
III patients generally experience long–term complications due to muscle weakness, inactivity and 
atrophy: 100% of type II and most type III patients present variable degrees of scoliosis, generally 
severe, and the majority have tendon retractions and joint contractures [1]. The classification into three 
forms does not fully reflect the clinical variability of these conditions, which is better depicted as a 
continuum, with many patients showing borderline phenotypes between two different forms. Indeed, 
alternative classifications have been proposed, including that of Dubowitz, who in 1995 suggested a 
decimalized classification for SMA patients which may more accurately describe the phenotypic 
complexity of the disease [2].  
SMA type I-III are autosomal recessive conditions, caused by loss of function of the survival motor 
neuron (SMN1) gene [3]. Independent of the phenotypic severity, most patients (about 95%) have the 
homozygous deletion of the SMN1 gene, whereas about 2–3% of individuals are compound 
heterozygotes for the deletion of one allele and point mutations of the other (see Wirth for a review) [4]. 
SMN1 and a nearly identical copy, SMN2, are located in a duplicated inverted region at 5q13. Both 
genes encode the SMN protein, but due to alternative splicing, the majority of SMN2 transcripts lack 
exon7 (SMN-delta7), and are unable to produce a sufficient amount of protein to prevent the onset of 
the disease. The SMN protein is expressed ubiquitously and is localized in the cytoplasm and in   
the nucleus. It has been shown that the levels of SMN protein are markedly reduced in SMA patients, 
both in the spinal cord in vivo and in cell cultures, and inversely correlates with the phenotypic 
severity [5–7]. The SMN protein has different functions, including SNRNPs biogenesis and axonal 
transport, but it is not established yet which of the SMN functions is responsible for the pathogenesis 
of SMA [8]. Patients can carry variable copy number of the SMN2 gene, higher copy numbers being 
generally associated with milder phenotypes [9–11].  
At present, no cure for SMA is available. One possible therapeutic approach is based on attempts at 
increasing the amount of SMN protein produced by SMN2 genes, through promoter activation, or 
reduction of exon7 alternative splicing, or both. Recently, evidence has been provided that SMN2 gene 
expression can be modulated in vivo and/or in vitro, using different strategies [12–28]. One possible 
alternative approach exploits the neuroprotective action of some compounds [29–31], aimed   
at preventing or delaying motor neuron loss. These compounds do not target the correction   Int. J. Mol. Sci. 2011, 12                 
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of the molecular defect of SMA since their mode of action is independent from the   
modulation of SMN2 gene expression. The efficacy of some compounds has been tested in clinical 
trials [21–23,32,33]. So far, none of the molecules evaluated has led to clinically meaningful 
improvements of motor function of patients. 
The availability of various potential approaches for the treatment of SMA has raised a number of 
issues, including the choice of the most appropriate outcome measures, the duration of trials,   
the clinical characteristics of patients recruited, the study design (open label versus double-blind,   
placebo-controlled trials). These aspects have been reviewed by Kaufmann and Muntoni [34] and  
were the subject of a workshop which was held in London in 2008, with the participation of 
representatives of the European Medicines Agency (EMEA) and of TREAT-NMD, a network of 
excellence of researchers in the field of neuromuscular disorders, funded by the European Union.  
The final document of the workshop is available on the TREAT-NMD website (http://www.treat-
nmd.eu/userfiles/file/general/EMEA_press_release.pdf).  
Some issues are particularly relevant in the design of clinical trials for chronic disorders like   
SMA: the availability of data on the natural history of the disease, the reliability and sensitivity of 
outcome measures, the duration of the studies, and the number and clinical homogeneity of 
participating patients. Given the rarity of SMA, it is reasonable to anticipate that forthcoming   
double-blind clinical trials should involve patients and neuromuscular centers from different countries 
and should be internationally coordinated, in order to recruit a sufficient number of patients to gain 
clinically meaningful and statistically significant results. 
Equally critical is the availability of reliable biomarkers whose relevance in the field of SMA is 
related to different aspects. An objective measurement: (1) can overcome the risk of placebo   
effect, which has already been evidenced in our previous study of phenylbutyrate [22]; (2) allows  
comparison of clinically heterogeneous individuals, unlike most clinical-functional outcome measures; 
(3) can help to distinguish responder and non-responder individuals to a given treatment, as a wide 
variability in the response to some compounds has been reported [16,17], and (4) may shorten the 
duration of the trials. Two classes of putative biomarkers can be identified in SMA (see Scheme 1 and 
Table 1): instrumental and molecular. The Compound Motor Action Potential (CMAP), the Motor Unit 
Number Estimation (MUNE), and the Dual-energy X-ray absorptiometry (DXA) are included in the 
first group. Among molecular biomarkers, only dosage of SMN gene products, either transcripts (both 
full length and del7 isoforms) or protein, is currently available.  
Table 1. Potential biomarkers in spinal muscular atrophy. 
Potential Biomarker  Pros  Cons 
Instrumental    
CMAP and MUNE    
    Both measures are related to phenotypic 
severity 
  MUNE does not appear related to 
motor function in a group of type II 
patients 
    Progressively decrease over time 
(MUNE is more stable in type III) 
  There is no evidence yet of 
correlations between motor function and 
CMAP variations Int. J. Mol. Sci. 2011, 12                 
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Table 1. Cont. 
    Are related to SMN2 copy number   
    Have been evaluated in an open phase II 
trial of valproic acid 
 
    CMAP, but not MUNE, increases with 
VPA 
 
DXA    
    Bone density increased after VPA 
treatment 
  The biological significance of BMD 
reduction in SMA patients is not 
established 
      It is not known whether BMD 
variations are related to the clinical 
outcome of treatment 
Molecular    
SMN protein quantification    
    SMN protein levels, as determined by 
cell immunoassay, are related to SMN2 
copy number  
  SMN protein levels are not related to 
clinical severity  
    For cell immunoassay, small amount of 
PBMC are sufficient for SMN 
quantification  
  No stabilization buffers are 
commercially available for total proteins  
    ELISA assay is sensitive down to 
magnitude of pg/mL of SMN protein  
  PBMC should be manipulated within 2 
hours from sampling  
      The minimum amount of peripheral 
blood necessary for SMN quantification is 
not known  
      It is not indicated for evaluation of 
candidate compounds which do not 
modify SMN levels 
SMN transcript quantification    
    Small amounts of blood (2.5 mL or less) 
are sufficient for mRNA quantification 
  It is not known if protein and transcript 
levels are related  
    Several stabilization buffers are 
available for multicenter clinical trials 
  It is unknown if transcript level 
variations are related to the clinical 
outcome of treatment 
    SMN transcripts are stable over time  
 
  It is unknown if transcript levels in 
blood and target tissues are related  
      It is not indicated for the evaluation of 
candidate compounds which do not 
modify SMN levels  
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Scheme 1. Schematization of biomarkers available in spinal muscular atrophy. 
 
2. Instrumental Biomarkers 
2.1. CMAP and MUNE 
CMAP and MUNE are electrophysiological tools which allow the evaluation of skeletal muscle 
innervation status [35]. While CMAP size variations may not be specifically related to neurogenic 
conditions, MUNE helps to distinguish loss of motor neurons and reinnervations [35,36]. These two 
measures have been evaluated in patients affected with different neurodegenerative conditions, 
including SMA [37–39]. Available data suggest that these electrophysiological tools are potentially 
useful as biomarkers in SMA for several reasons. Swoboda et al. have performed a longitudinal natural 
history study on 89 SMA patients affected with forms of various severity and found that both measures 
had significantly lower values compared to controls and that they were related to the phenotypic 
severity [39]. However, while a clear difference was evident for different groups of patients, CMAP 
and MUNE were not predictive of the phenotypic severity of individual patients, since a certain degree 
of overlapping was observed among groups. Similar findings were reported by another study [37] that 
evaluated the strength of elbow flexion through a functional score (measured by the modified Medical 
Research Council scale) in 13 type-II/III patients. The data obtained, when related to MUNE values, 
indicated that the latter are not predictive of the functional outcome. However, in this study, the age 
range of patients and the number of years of disease elapsed from diagnosis was very wide, which may 
have impaired the functional evaluation of patients.  Int. J. Mol. Sci. 2011, 12                 
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It has also been shown that CMAP and MUNE progressively decrease over time: Swoboda et al. 
found a progressive reduction of both parameters, more marked during the first years of postnatal  
life [39]. In type III patients, MUNE appeared to be more stable.  
In our opinion, the results of electrophysiological evaluations should be integrated with the natural 
history data of the disease: in the case of SMA type I, it has been shown that the survival of patients 
has markedly increased over the last years, likely due to the more frequent application of proactive 
clinical interventions [40]; however, no data are available on the impact of longer survival on CMAP 
and MUNE variations. Regarding SMA type II, to our knowledge, some studies on the natural history 
were performed several years ago, without the confirmation of the molecular defect of the SMN1  
gene [41,42] and, thus, these data should be interpreted cautiously. Deymeer et al. [43] performed the 
longitudinal evaluation of muscle strength of 10 type IIIb subjects, over a period of more than   
10 years, and reported a slow progressive decline in muscle function of these patients, more evident in 
some muscle groups. The Authors related the functional decline to the progressive loss of motor 
neurons, rather than to the onset of complications of the disease, like joint contractures or scoliosis.  
The discrepancy between the results of Deymeer et al. and the stability of MUNE values reported by 
Swoboda et al. [39] in type III individuals, may be related to the different duration of the studies: A 
longer follow-up of patients through MUNE may disclose that, albeit slow, the loss of motor units is 
continuous. In our opinion, data on the natural history of the disease, both at clinical and instrumental 
levels, are critical for the identification of the endpoint and the duration assessment of clinical trials: 
while the stabilization or, hopefully, an increase in CMAP/MUNE could be considered as a marker  
of efficacy of a given compound in type I or type II patients, in the case of type III individual, this  
may be not sufficient.  
It has been also shown that both CMAP and MUNE are related to SMN2 copy number [39]: 
Although the gene copy number is not predictive of the phenotypic severity of SMA of individual 
patients, the modifying effect of SMN2 genes has been demonstrated in several clinical studies,   
and also in murine models as SMA-like mice with higher hSMN2 copy number display milder 
phenotypes [44]. In our recent study on the effect of salbutamol treatment, we demonstrated for the 
first time that patients with higher SMN2 copy numbers have a better chance to respond to treatment at 
the molecular level (see below).  
The use of CMAP and MUNE assessment in clinical trials as surrogate outcome measures has been 
evaluated in a recent open pilot trial of valproic acid in SMA patients [32], where Swoboda et al. 
found a statistically significant increase in CMAP (but not in MUNE) during treatment. However, it is 
not definitively established whether CMAP and MUNE are suitable as biomarkers and/or surrogate 
outcome measures in SMA since in addition to several pros, there are cons which undermine their 
applicability in clinical trials. In particular, there are still some crucial aspects that have not been 
defined: (1) CMAP has been evaluated in a double-blind study of valproic acid but the results of the 
study were not positive [33]; (2) CMAP and MUNE do not have prognostic value in individual 
patients, as discussed above, and (3) there is no evidence yet of possible correlations between 
variations of motor function and electrophysiological parameters.  Int. J. Mol. Sci. 2011, 12                 
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2.2. DXA 
DXA is the most generally accepted tool to measure bone mineral density (BMD) and it is based on 
X-ray absorption, generally evaluated at the level of lumbar vertebrae [45]. In most patients with 
limited motility, a reduction in BMD is often observed and it is a very common event in patients 
affected with neuromuscular disorders, like Duchenne muscular dystrophy (DMD) [46]. However, 
some studies have suggested that a primary bone remodeling defect may be present in SMA. In 
particular, Kathry et al. reported that young SMA patients show, as expected, a reduction of BMD 
compared to age-matched controls, but BMD reduction was significantly higher than that observed in 
age-matched DMD patients [46]. BMD loss was higher in non-ambulant SMA patients and in type II 
compared to type III. In another study, Kinali et al. found that in younger SMA patients (below 
10 years of age) BMD was not reduced, but they did not observe the physiologic increase in BMD 
which normally occurs above this age, resulting in a relative reduction in BMD in SMA patients [47]. 
Interestingly, in a mouse model of SMA, Shanmugarajan et al. reported an osteoporotic phenotype in 
affected mice, suggesting a role of SMN protein in bone remodeling [48]. For these reasons, DXA is a 
candidate biomarker in SMA. To our knowledge, BMD has been evaluated only in one clinical trial of 
SMA patients, the open label of valproic acid cited above [32], where it increased during treatment 
compared to baseline. However, the biological and clinical significance of this finding is still unclear 
and it is not known whether it is related to the clinical outcome. Also in the case of this tool,   
double-blind, placebo-controlled studies are necessary to confirm the putative usefulness of DXA as a 
surrogate outcome measure in SMA clinical trials. 
3. Molecular Biomarkers 
At present, the dosage of SMN transcripts or protein in peripheral blood is the only potential 
molecular biomarker available. However, possible variations of SMN transcripts/protein levels as 
evaluated in leukocytes may not reflect the real effect of pharmacological treatment in target tissues, 
like the spinal cord and, possibly, skeletal muscle. Tissues other than blood, like skin or muscle 
biopsies, have been not considered so far for molecular biomarker analysis in SMA patients, due to the 
more invasive sampling procedures. This approach has been recently followed in a phase II clinical 
trial of the efficacy of PTC124 in patients affected by DMD who have undergone muscle biopsy 
before starting and after 24 weeks of treatment to evaluate the re-expression of dystrophin (see 
www.clinicaltrials.gov website). Further studies are necessary to evaluate the feasibility of a similar 
approach in SMA patients. 
3.1. SMN Protein Quantification 
SMN protein quantification is considered by most researchers as the most suitable and sensitive 
molecular biomarker for SMA. It has been shown that SMN protein levels are reduced in the spinal 
cord of SMA patients [4]. However, this is not demonstration for other tissues, like blood, which is the 
ideal target for biomarker analysis in vivo. Several techniques have been used for SMN protein 
quantification. Western blot was used in several in vitro and in vivo studies, mainly aimed at 
evaluating possible variations of SMN protein levels related to pharmacological treatment [17–18,24]. Int. J. Mol. Sci. 2011, 12                 
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However, this assay has several limitations, essentially related to its semiquantitative nature, requiring 
normalization  versus  housekeeping proteins, whose levels are subjected to wide interindividual 
variations. An alternative approach has been proposed by Kolb et al., who developed an immunoassay 
suitable for SMN protein quantification in peripheral blood mononuclear cells (PBMC), through which 
they could demonstrate a correlation with SMN2 copy number [49]. However, these authors found a 
reduction of SMN levels only in PBMC of type I patients, and did not find any correlation between 
protein levels and phenotypic severity. These findings clearly question the usefulness of quantifying 
SMN protein during clinical trials. ELISA assay is considered more sensitive and adequate for protein 
quantification since it does not require normalization to other proteins, given that SMN levels are 
quantified with respect to a standard curve constructed with serial dilutions of purified protein. To 
date, three different assays have been developed and validated. The first one, described by   
Thi Man et al., is suitable only for in vitro applications [50]. More recently, Assay Design Inc. has 
developed a commercial assay, in collaboration with SMA Foundation, which has a very high 
sensitivity for SMN protein detection (Assay Designs
® SMN (human) Enzyme Immunometric Assay 
kit). The third assay was recently published by Piepers et al., who used it to quantify SMN protein 
variations during valproic acid treatment of six type II/III patients [51]. These authors showed that 
their assay is sufficiently sensitive to measure SMN variations related to treatment, and also found that 
SMN protein levels in PBMC of patients are reduced compared to healthy controls. Although these 
results are promising, the small number of samples analyzed (only four healthy controls), the absence 
of age-matched controls, of a placebo arm and of clinical-molecular correlation, do not allow firm 
conclusions to be drawn on the validity of SMN protein dosage in clinical trials. 
SMN protein dosage as a biomarker or surrogate outcome measure has some further technical 
drawbacks which impair the application of this assay in the context of multicenter double-blind clinical 
trials: PBMC should be processed within two hours from sampling to reduce possible biases due to cell 
death or to variations in protein levels; there are no commercially available stabilization buffers 
suitable to “snapshot” SMN expression at the moment of blood samplings; protein extraction requires 
larger peripheral blood draws often hard to obtain from very hypotonic or very young patients. Finally, 
SMN protein quantification is not indicated in the evaluation of those compounds whose mode of 
action is independent from SMN modulation, such as neuroprotective agents. 
3.2. SMN Transcript Quantification 
Several assays have been developed and validated for SMN  transcript analysis, aimed   
at determining either full length (SMN-fl) or del7 (SMN-del7) isoforms, or the SMN-fl/del7   
ratio [16,46–49]. These assays were developed for at least two purposes: (a) establishing whether 
SMN-fl transcripts are reduced in patients compared to controls, also in non-target tissues, like 
peripheral blood; and (b) evaluating the molecular effect of therapies aimed at modifying SMN levels 
in vivo. These therapies may be based on the activation of the SMN2 gene promoter, on the reduction 
of the alternative splicing of exon7, or both. To differentiate the effect of different therapeutic agents, 
it is essential to evaluate both SMN-fl and del7 isoforms, since promoter activation only would lead to 
an increase in both isoforms. On the other hand, if a therapeutic agent acts mainly by reducing the 
alternative splicing, an increase in SMN-fl levels and a concomitant reduction in the SMN-del7 Int. J. Mol. Sci. 2011, 12                 
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isoform should be observed. Some researchers propose to evaluate possible variations of SMN-fl/del7 
ratio only, but in this case, putative effects on promoter activation cannot be measured [18].  
The results of different studies on SMN transcript levels have been discordant. In particular, a 
correlation between SMN2 copy number and transcript levels has been found by Sumner et al. [52] 
and by Vezain et al. [54], but not by Simard et al. [53] or by ourselves [55]. Vezain et al. and Tiziano 
et al. found a correlation between SMA phenotype and transcript levels, whereas Brichta et al. [17], 
Sumner et al. and Simard et al. did not. Significant differences between SMN-fl transcript levels of 
type I patients and controls were found by Brichta et al. and Sumner et al. but not by Simard et al. For 
the first time, we have recently shown that SMN-fl transcript levels are significantly lower in type II 
and III patients compared to controls, although not predictive of the phenotypic severity in individual 
patients [55]. The differences observed in different studies may be related to the methods used for 
SMN-fl level assessment. The majority of SMN mRNA assays are based on relative semiquantitative 
PCR in which transcript levels are determined by normalization with respect to housekeeping gene 
transcript levels, used as internal controls [52–54]. However, we and others have demonstrated that the 
expression levels of these genes vary widely in the general population and, or, can be probably 
affected by pharmacological treatments or metabolic status, thus reducing the sensitivity of the 
previously published assays [55,56]. The assay described by Brichta et al. is based on real time PCR 
and relative standard curves and SMN levels are measured as folds of variation compared to serial 
dilution of a control sample [17]. In our opinion, this approach may be considered unbiased only if the 
same sample is always used as control, otherwise it should be assumed that SMN levels in different 
control individuals are similar. We recently demonstrated that SMN-fl levels vary widely in control 
individuals, although they do not show a Gaussian distribution [55]. Our assay is based on absolute 
real time PCR. SMN-fl transcript levels are extrapolated from standard curves, constructed by serial 
dilutions of an external standard and are measured as number of mRNA molecules/ng of total RNA. 
The main advantage of this approach is that it allows quantification of SMN-fl levels independently  
from housekeeping control transcripts. On the basis of our results, the International Coordination 
Committee, a U.S. based organization of SMA researchers and clinicians aimed at harmonizing the 
outcome measures in clinical trials, has indicated our assay as the most appropriate to be used for SMN 
transcript analysis during clinical studies in SMA. Very recently, we applied this assay to evaluate the 
effect of salbutamol, a candidate compound for the treatment of SMA, on SMN expression [25]. 
Twelve patients were included in this study, who took oral salbutamol for six months: in all patients 
we found an increase in SMN-fl levels in PBMC, and all individuals at six months reached the median 
transcript levels of controls. However, at present it is not possible to establish whether the restoration 
of SMN levels in blood is predictive of the increase in spinal cord, which may be critical for the 
recovery of SMA phenotype. For the first time, we found also that the molecular response to 
salbutamol was higher in individuals with a larger number of copies of SMN2 genes, suggesting that 
these individuals are better responders to the compound and that SMN2 copy number can be included 
as a randomization parameter during the design of double-blind, placebo-controlled trials. The efficacy 
of other compounds modulating SMN expression has been evaluated in vivo by means of different 
mRNA quantification assays. In our previous study on the effect of phenylbutyrate, we found 
considerable variations both among different subjects and among different blood samples from the 
same subject [16]. In another open-label trial with valproic acid, SMN2 mRNA levels were found Int. J. Mol. Sci. 2011, 12                 
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elevated in seven patients and unchanged or decreased in 13 patients [17]. Similarly, in the most recent 
open label study of the effect of valproic acid, fluctuation of SMN mRNA levels throughout drug 
treatment was reported in patients showing increased, decreased or unaltered levels [32]. In our 
opinion, the variability observed in the molecular response to treatment may be related to the different 
assays used for transcript analysis, to the different molecular efficacy of the compounds, or to the 
individual response of each patient (responder versus non-responder individuals).  
Some technical advantages support SMN transcript analysis as a biomarker/surrogate measure for 
SMA, compared to protein analysis, including the availability of several stabilization buffers which 
allow the samples to be preserved from RNA degradation and gene expression variations for up to five 
days, and the small amount of blood (down to 0.5 mL) necessary for the assay. These aspects are very 
relevant in the context of multicenter trials, especially when dealing with severely hypotonic patients.  
SMN transcript analysis is not free from some drawbacks which need to be considered if this tool is 
to be accepted as standard biomarker in SMA. First, it should be established whether SMN protein and 
transcripts levels are related. This is a critical issue, since to be therapeutically effective, the increase in 
SMN-fl levels should result in a comparable increase in SMN protein. The presence of such correlation 
is not obvious, since the dynamics and the half-life of mRNAs and proteins are not necessarily 
comparable. However, in our opinion, this aspect is more relevant in studies aimed at defining the 
intracellular mechanisms leading to SMN increase, rather than in the context of a clinical trial. Indeed, 
independently from transcript/protein level correlations, transcript variations may be suitable to 
identify responders and non-responders to a given treatment or may be predictive of the clinical 
outcome. The latter is another critical issue: the demonstration of correlations between clinical and 
molecular response to a given treatment are still missing. These data can be provided only by   
double-blind, placebo-controlled studies, due to the placebo effect which is very common in open label 
studies. Other aspects should be clarified before stating that SMN transcript analysis is a biomarker for 
SMA: (1) like in many other conditions, PBMCs are not target cells in SMA and it should be 
demonstrated that SMN levels in blood reflect those found in target tissues, i.e., the spinal cord but 
also skeletal muscle (to our knowledge, a single study on animal models is currently available [57]); 
(2) like SMN protein dosage, transcript analysis is not indicated for the evaluation of potential 
therapeutic compounds that do not modify SMN levels.  
4. Conclusions 
The recent move of SMA research from basic to clinical has raised the necessity to develop reliable 
clinical and biological markers to monitor the response of SMA patients to therapeutic interventions. 
While validated clinical tools have been developed, and a general consensus has been reached on the 
most suitable and reliable outcome measures, none of the biomarkers described above can be 
considered the gold standard. Indeed, while each of them presents certain positive aspects, there are 
still several crucial issues (summarized in Table 1) which should be resolved before stating that a 
biomarker for SMA is available. In our opinion, the most promising biomarkers are MUNE and SMN 
transcript quantification, in terms of feasibility, costs and availability of preliminary data. Two 
complementary approaches may provide the proof of concept needed for biomarker validation: 
preclinical studies and double-blind, placebo-controlled studies. Preclinical studies on SMA animal Int. J. Mol. Sci. 2011, 12                 
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models can provide information on some issues like correlations between transcript and protein levels 
and between target and non-target tissues, being the phenotype of murine models the most extensively 
characterized. Double-blind, placebo- controlled studies are crucial to evaluate the appropriateness of 
biomarkers, on the basis of correlations with the clinical outcome.  
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